EXAGEN Inc. Q3 2025 (9 Months Ended September 30, 2025) TL;DR
Financial Performance & Liquidity: Revenue demonstrated strong growth, increasing 19.0% year-to-date (YTD) to $49.9M, driven by volume and higher Average Selling Price (ASP). Gross Margin improved slightly to 59.3%. Despite an improved Operating Loss ($9.1M vs. $10.3M prior year), the Net Loss widened to ($15.3M) YTD due primarily to non-operating charges, specifically increased interest expense ($3.0M) and a $3.1M non-cash charge related to the revaluation of the Warrant Liability. Q3 revenue grew significantly to $17.2
...